Blueprint Medicines Presents P-II Trial (PIONEER) of Ayvakit (avapritinib) for Indolent Systemic Mastocytosis at AAAAI 2023
Shots:
- The P-II trial evaluating Ayvakit (25mg, qd) + BSC vs PBO + BSC in 251 patients at 49 sites in 13 countries showed an improvement on 1EPs & 2EPs i.e., a rapid, durable & reduction on all pathological mast cell burden measures @24wks.
- ≥50% reduction in serum tryptase/KIT D816V variant allele fraction/bone marrow mast cell aggregates (53.9% vs 0%)/ (67.8% vs 6.3%)/ (52.8% vs 22.8%), ≥30% & ≥50% reduction in TSS (45.4% @24wks. & 60.7% @48wks. vs 29.6% @24wks.) & (24.8% & 39.3% vs 9.9%)
- Improvement in mean change in most sev. symptom score, mean percent change in MC-QoL total score (-34.3% vs -17.9%), was well-tolerated with a favorable safety profile, SAEs (11.3% vs 5.0%). The company submitted Ayvakit’ sNDA to the US FDA & type II variation MAA to the EMA. The US FDA has granted priority review to Ayvakit’ sNDA with a PDUFA of May 2023
Ref: PRNewswire | Image: Blueprint Medicines
Related News:- Blueprint Medicines Receives the US FDA’s Acceptance of sNDA for Ayvakit (avapritinib) to Treat Indolent Systemic Mastocytosis
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
